Novartis Pharma to Market Femara, Ethical Agent for Postmenopausal Breast Cancer, in Japan.Tokyo, Japan, Jan 24, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Novartis Pharma announced on January 23 that it has obtained approval for its proprietary agent, Femara Tablet 2.5mg (letrozole), from the Ministry of Health, Labor and Welfare. The new agent, which is an aromatase inhibitor aromatase inhibitor n. A drug that inhibits tumor growth, especially breast cancer, by inhibiting the enzyme aromatase and thereby lowering estrogen levels in the blood or in tumor tissues. , is indicated for the treatment of postmenopausal post·men·o·paus·al adj. Of or occurring in the time following menopause. postmenopausal Change of life Gynecology adjective Referring to the time in ♀ when menstrual periods stop for ≥ 1 yr breast cancer. In particular, the agent helps reduce the risk of recurrence and achieve a prolonged disease-free survival disease-free survival Oncology The time that a person with a disease lives without known recurrence; DFS is major clinical parameter used to evaluate the efficacy of a particular therapy, which is usually measured in 'units' of 1 or 5 yrs. See Cure, Remission. . The drug can exert beneficial effects with once-a-day dosage. Currently, Femara is available in over 90 countries worldwide. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion